Anandamide transport inhibition by the vanilloid agonist olvanil

European Journal of Pharmacology

Volumn 364, Issue 1, 1999, Pages 75-78

  Beltramo, Massimiliano ^a   Piomelli, Daniele ^a  

^a NEUROSCIENCES INSTITUTE   (United States)

Author keywords

Analgesia; Anandamide; Cannabinoid; Capsaicin; Olvanil; Transport

Indexed keywords

ANANDAMIDE; CAPSAICIN; CAPSAZEPINE; N (4 HYDROXYPHENYL)ARACHIDONYLETHANOLAMIDE; OLVANIL; UNCLASSIFIED DRUG; VANILLOID RECEPTOR;

ARTICLE; ASTROCYTOMA CELL; CONTROLLED STUDY; DOSE RESPONSE; DRUG TRANSPORT; HUMAN; HUMAN CELL; IN VITRO STUDY; ISOTOPE LABELING; PRIORITY JOURNAL;

AMIDOHYDROLASES; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARACHIDONIC ACIDS; ASTROCYTOMA; BIOLOGICAL TRANSPORT; BRAIN; CAPSAICIN; DEPRESSION, CHEMICAL; HUMANS; POLYUNSATURATED ALKAMIDES; RATS; RECEPTORS, DRUG; TUMOR CELLS, CULTURED;

EID: 0032902926     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(98)00821-8     Document Type: Article

References (21)

1. Beltramo M., Stella N., Calignano A., Lin S.Y., Makriyannis A., Piomelli D. Functional role of high-affinity anandamide transport, as revealed by selective inhibition. Science. 277:1997;1094-1097.
2. Bisogno, T., Melck, D., Ross, R., Brockie, H., De Petrocellis, L., Pertwee, R., Di Marzo, V., 1998. Interactions between vanilloids and the endogenous cannabinoid system. International Cannabinoid Research Society, 1998 Symposium on the Cannabinoids, La Grande Motte, France, p. 19.
3. Brand L., Berman E., Schwen R., Loomans M., Janusz J., Bohne R., Maddin C., Gardner J., Lahann T., Farmer R., Jones L., Chiabrando C., Fanelli R. NE-19550: a novel, orally active anti-inflammatory analgesic. Drugs Exp. Clin. Res. 13:1987;259-265.
4. Calignano A., La Rana G., Beltramo M., Makriyannis A., Piomelli D. Potentiation of anandamide hypotension by the transport inhibitor, AM404. Eur. J. Pharmacol. 337:1997;R1-R2.
5. Calignano A., La Rana G., Giuffrida A., Piomelli D. Control of pain initiation by endogenous cannabinoids. Nature. 394:1998;277-281.
6. 50) of an enzymatic reaction. Biochem. Pharmacol. 22-23:1973;3099-3108.
7. Cravatt B.F., Giang D.K., Mayfield S.P., Boger D.L., Lerner R.A., Gilula N.B. Molecular characterization of an enzyme that degrades neuromodulatory fatty acid amides. Nature. 384:1996;83-87.
8. Desarnaud F., Cadas H., Piomelli D. Anandamide amidohydrolase activity in rat brain microsomes: identification and partial characterization. J. Biol. Chem. 270:1995;6030-6035.
9. Devane W.A., Hanus L., Breuer A., Pertwee R.G., Stevenson L.A., Griffin G., Gibson D., Mandelbaum D., Etinger A., Mechoulam R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 258:1992;1946-1949.
10. Dickenson A., Hughes C., Rueff A., Dray A. A spinal mechanism of action is involved in the antinociception produced by the capsaicin analogue NE-19550 (olvanil). Pain. 43:1990;353-362.
11. Dray A., Bettaney J., Rueff A., Walpole C., Wrigglesworth R. NE-19550 and NE-21610, antinociceptive capsaicin analogues: studies on nociceptive fibres of the neonatal rat tail in vitro. Eur. J. Pharmacol. 181:1990;289-293.
12. Fride E., Mechoulam R. Pharmacological activity of the cannabinoid receptor agonist, anandamide, a brain constituent. Eur. J. Pharmacol. 321:1993;313-314.
13. Hillard C.J., Wilkison D.M., Edgemond W.S., Campbell W.B. Characterization of the kinetics and distribution of N-arachidonylethanolamine (anandamide) hydrolysis by rat brain. Biochim. Biophys. Acta. 1257:1995;249-256.
14. Hughes S.R., Buckley T.L., Brain S.D. Olvanil: more potent than capsaicin at stimulating the efferent function of sensory nerves. Eur. J. Pharmacol. 219:1992;481-484.
15. Liu L., Lo Y.-C., Chen I.-J., Simon S.A. The responses of rat trigeminal ganglion neurons to capsaicin and two nonpungent vanilloid receptor agonists, olvanil and glycerol nonamide. J. Neurosci. 17:1997;4101-4111.
16. Randall M.D., Kendall D.A. Endocannabinoids: a new class of vasoactive substances. Trends Pharmacol. Sci. 19:1998;55-58.
17. Richardson J.D., Aanonsen L., Hargreaves K.M. SR 141716A, a cannabinoid receptor antagonist, produces hyperalgesia in untreated mice. Eur. J. Pharmacol. 319:1997;R3-R4.
18. Szallasi A., Blumberg P.M. Vanilloid receptors: new insights enhance potential as a therapeutic target. Pain. 68:1996;195-208.
19. Ueda N., Kurahashi Y., Yamamoto S., Tokunaga T. Partial purification and characterization of the porcine brain enzyme hydrolysing and synthesizing anandamide. J. Biol. Chem. 270:1995;23823-23827.
20. Wagner J.A., Varga K., Ellis E.F., Rzigalinski B.A., Martin B.R., Kunos G. Activation of peripheral CB1 cannabinoid receptor in haemorrhagic shock. Nature. 390:1997;518-521.
21. Winter J., Walpole C.S.J., Bevan S., James I.F. Characterization of resiniferatoxin binding sites on sensory neurons: co-regulation of resiniferatoxin binding and capsaicin sensitivity in adult rat dorsal root ganglia. Neuroscience. 57:1993;747-757.